Clinical Trial

Manipulating the Peri-Infarct Area Using Maraviroc to Enhance Motor Skills After Stroke

Study acronym: MASTER
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
MASTER is a single-center, patient and investigator-blinded, Randomized Controlled Trial (RCT) to compare the efficacy of Maraviroc, a C-C chemokine receptor 5 (CCR5) antagonist, against placebo regarding motor function and motor learning skills in the first 3 months after ischemic stroke.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-07-14.
Status change: Not Yet Recruiting → Recruiting 2025-08-07
Trial Details
NCT Number NCT07080567
Lead Sponsor Emmanuel Carrera
Conditions Ischemic Stroke, Stroke, Stroke Acute
Enrollment 80 participants
Start Date 2025-07-14
Primary Completion 2027-12 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2025-08-12